A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer.
Wondering if you qualify as a candidate for this trial? Visit the "View Trial" button below and print the the trial's details to discuss with your Cancer Care Northwest physician.
For More Information
If you're interested in participating in this clinical trial, please complete the form below. A member of the Cancer Care Northwest Clinical Research Department will review your information and contact you shortly.
